Breast Cancer Clinical Trial
Official title:
Pilot Study: Post-operative Outcomes of Enhanced Energy Delivery Dissection for Mastectomy Breast Flap Creation With Immediate Breast Reconstruction
Principal Investigator: Sheldon Feldman, MD Co-Principal Investigator: Mohamad Sebai, MD
Department of Surgery, Montefiore Medical Center - Einstein College of Medicine
Title Pilot Study: Post-operative outcomes of enhanced energy delivery dissection for
mastectomy breast flap creation with immediate breast reconstruction Goal Determine the
feasibility of a study design that includes the evaluation of breast flap viability,
postoperative surgical site drainage, post-operative pain/surgical site complications, time
to complete mastectomy with Photonblade (PB) vs traditional electrosurgery devices.
Overall outcome If determined feasible, consider going to clinical trial. Timing 6 months
starting after execution of contract Study population Women between 18-65 years old Choose
bilateral mastectomy followed by immediate breast reconstruction (through tissue expander
insertion) No inflammatory breast cancer/no radiotherapy Study design Single blinded,
randomized controlled pilot study (n=15) Only breast surgeon knows which device was used for
each breast Study feasibility endpoints Flap Viability - compare perfusion, using PhotonVue,
of flaps creation using PB vs Bovie (left is better, right is better or they are similar)
Site drainage - Measure drainage volume and duration Pain scores and complications -
Subjective pain assessment on days 1, 2, 3, 7 and 30 post-op. (Pain visual Analog Scale).
Surgical site complications will be recorded up to 30-days post-op. Time to completion of
mastectomy flap using PB vs Bovie will be recorded. (Time in minutes between initial incision
and completion of mastectomy for each side) Analysis Descriptive analysis will be performed
to examine data distribution, missing data and data errors.
Continuous variables will be summarized using means or medians; categorical variables will be
summarized using proportions.
CLINICAL TRIAL Objectives Determine if post-op flap viability differs between women getting
mastectomy flap creation using PB vs Bovie Determine if post-op site drainage measures
differs between two devices Determine if post-op pain measures differ when using PB vs Bovie
Determine if time to mastectomy flap creation differs between using Bovie and PB
Pilot Study: Post-Operative Outcomes of Enhanced Energy Delivery Dissection for Mastectomy
Breast Flap Creation with Immediate Breast Reconstruction
Principal Investigator Sheldon M. Feldman, MD Chief, Division of Breast Surgery & Breast
Surgical Oncology Director, Breast Cancer Services; Professor of Surgery Montefiore Medical
Center- Albert Einstein College of Medicine New York, NY Email: sfeldman@montefiore.org
Co-Principal Investigator Mohamad E. Sebai, MD General Surgery Resident Montefiore Medical
Center- Albert Einstein College of Medicine New York, NY Email: msebai@montefiore.org
Biostatistics: Michael Parides, PhD Professor Department of Surgery Montefiore Medical
Center- Albert Einstein College of Medicine New York, NY Email: mparides@montefiore.org
Patricia Friedmann, MS Assistant Professor Department of Surgery Montefiore Medical Center-
Albert Einstein College of Medicine New York, NY Email: patricia.friedmann@einstein.yu.edu
1. Rationale:
Breast cancer is the second leading cause of cancer deaths among women in the United
States. The American Cancer Society (ACS) estimated that 230,480 new cases of invasive
breast cancer, a 19.8% increase over the ACS's 2009 estimates, and 39,520 deaths due to
the disease would occur in 2011(1). In addition to breast conserving treatments,
mastectomy can be an important and definitive treatment option for selected patients.
Breast reconstruction has been shown to improve quality of life scores in patients
treated with mastectomy (2). Immediate Breast reconstruction (IBR) after mastectomy has
typically been performed using prosthetic devices or autologous tissue transplantation
(3).
Skin sparing mastectomy is a commonly used method of surgical treatment for breast
cancer that allows for immediate breast reconstruction (4). Preservation of the breast
skin envelope (breast flap) provides excellent cosmetic results and the overall
sensation is largely maintained (4-7). An important factor for breast reconstruction
success is the creation of a well perfused breast flap, with minimum flap injury (8-10).
One of the major complications associated with this surgery is breast flap death
(necrosis, 11). This complication then requires the patient to endure further
operations, prolonged hospital stays, and higher hospital costs. Rates of native skin
flap ischemia and necrosis after skin-sparing mastectomy vary from 2% to 30% (11,12).
Some evidence suggests that this flap necrosis could be due to decreased or loss of
viability/ blood supply (ischemia) as a result of the thermal injury caused by
traditional dissection devices (Bovie cautery) use for breast flap creation (13). The
use of traditional dissection devices remains to be the most common in creating breast
flaps, despite how old this technology is. Newer dissection devices that uses modern
technology for enhanced energy delivery has been introduced recently, however, there is
still paucity of data in regards to the clinical outcomes of using these devices for the
cases of mastectomy and IBR.
PhotonBlade (Invuity, San Francisco, CA, USA) has been approved by United States Food
and Drug Administration (FDA). PhotonBlade is a dynamic precision illuminator with
enhanced energy delivery dissection device. The dynamic precision illumination is a
thermally cool illumination technology that allows a uniformal illumination without
glare or shadow (14). The enhanced energy delivery technology allows low thermal spread,
surgeon controlled edge temperature, and wet field use (14). As such, PhotonBlade allows
better blade control for achieving adequate visualization, hemostasis, with a minimum
collateral damage to the created flap. The use of PhotonBlade demonstrated the least
penetrating thermal tissue damage/spread when compared to other modern dissection
devices (Valleylab Pencil, Valleylab EDGE Coated Pencil, PlasmaBlade 3.0S and
PlasmaBlade 4.0)(15).
The aim of this pilot study is to evaluate the feasibility of measuring breast flap
viability, postoperative surgical site drainage, post-operative pain/ surgical site
complications, and time to complete mastectomy with the use of enhanced energy delivery
dissection devices, PhotonBlade, in comparison to traditional electrosurgery devices.
2. Study Design:
This is a single-blinded, controlled pilot study (n=15) to determine the feasibility of
comparing postoperative flap viability and surgical site drainage between patients
randomized to breast flap creation by PhotonBlade on one breast and by a Bovie cautery
(Control) for the contralateral breast. Candidates will have elected to undergo
bilateral post-mastectomy IBR through tissue expander insertion. Participants meeting
inclusion criteria will be enrolled and baseline data collection completed prior to
randomization and surgery.
Patients will be blinded in regards to which side will be treated with which cautery
device. Initially, the plastic surgeon will be blinded as to the electrocautery device
used on the breast until after completing the flap evaluation, when the plastic surgeon
will be unblinded. This is done to allow the plastic surgeon to use same dissection
device for each breast side during the reconstruction part of the surgery. Only the
breast oncology surgeon has initial knowledge of which device was used for each breast
flap. Patient-specific surgical details will be recorded intraoperatively. Following the
surgery, post-operative flap perfusion will be recorded using PhotonVue imaging system
and will be used a tool for flap viability assessment by the plastic surgeon clinical
evaluation. Surgical site drainage will be measured until drainage removal. Post-
operative pain scores and the occurrence of adverse events will be recorded up until 30
days post-op. Before starting enrollment, the breast and plastic surgeons will do up to
5 non-pilot study cases using PhotonBlade in order be familiar with the device. Figure 1
demonstrates study design schema for the pilot study. Figure 1 does not include the up
to 5 non-pilot study cases.
3. Sample Size:
The proposed sample size of 15 patients for this pilot study is based on ensuring
acceptable operating characteristics for the decision process for assessing feasibility.
Feasibility will be determined by whether breast flaps created using the PhotonBlade
have better viability than those created using Bovie cautery. The null hypothesis is
that the probability that flaps created using the PhotonBlade have better viability than
those created by Bovie cautery (π) is less than one-half. The alternative hypothesis is
that this probability is greater than one-half. Feasibility is defined as observing
superior viability with the PhotonBlade in 10 or more of the 15 randomized patients. The
sample size of 15 ensures that the false positive rate (Type I error) for determining
feasibility using this definition is 0.15 (i.e., the binomial probability of observing
10 or more patients with better viability using the PhotonBlade out of 15 total patients
given π=0.50 is 0.15). This probability (i.e., power) is 0.85 under the alternative that
π=0.75, and 0.72 under the alternative that π=0.70.
4. Randomizations:
Patients will have their breasts randomized, with the left breast receiving mastectomy
flap creation using the randomized assignment (PhotonBlade or Bovie cautery), and the
right breast receiving the other approach. Randomization of breast side will be
performed by the breast surgical oncologist on the day of the surgery from a master
randomization list created by the study statistician. A simple randomization scheme will
be employed.
5. Flap Perfusion Viability This will be done by the plastic surgeon who will evaluate the
flaps by using PhotonVue near-infrared fluorescence images for flap perfusion of each
breast flap after the mastectomy and before the immediate breast reconstruction.
PhotonVue is an FDA approved fluorescence imaging system that is used as an adjuvant
assessment tool of tissue perfusion, and blood circulation of free flaps used in
plastic, micro- reconstruction, and organ transplant surgeries.16 PhotonVue images of
the flap perfusion will be taken at 45-60 seconds post ICG injection.
For each case, the plastic surgeons will report one of three outcomes: a) Left breast
flap has a better viability, b) Right breast flap has a better viability, or c) both
sides are similarly viable. After unbinding, the results will be reported according to
the usage of PhotonBlade or Bovie cautery for each side.
6. Surgical Site Drainage Assessments This will be done by measuring surgical site drainage
volume and days until removal of the drains for each breast.
7. Post-Operative Pain Assessment Pain Visual Analog Scale will be used to assess pain
preoperatively and postoperatively. Patient will be asked to report their pain score for
each breast using the validated Pain Visual Analog Scale (Appendix A). Short term post
pain will be reported as the mean of pain scores up to day 7, and longer term post op
pain will be the pain score at day 30 post op. Up to 30 days post-op follow-up medical
records will be used to collect incidences of post op surgical site complications.
Additionally, patients will be asked to report their experience at the 30 days follow up
appointment. Their response will be recorded. They will be also asked to report one of
the following: 1) I believe the right breast had a better patient reported outcomes
based on my experience, 2) I believe the left breast had a better patient reported
outcomes based on my experience, or 3) I believe both breasts had similar patient
reported outcomes based on my experience. After completion of data collection of the 30
days post-op follow up visit, patients will be unblinded and they will be made aware of
which dissection device was used for which breast.
8. Time for Mastectomy Completion This will be done by measuring time in minutes from the
incision time until the completion of mastectomy for each breast side.
9. Outcome Evaluation:
Sources of data: The sources of the data are our institutional medical records system.
Data collection: Data will be collected from the medical records through chart review
process done by study team officials.
Data analysis: The main analytic goal of this pilot study is assessment of feasibility
which is based on the number of patients with PhotonBlade flaps having better viability
than Bovie flaps (a "success"), and quantified by the exact (binomial) probability of
observing at least that many successes if the true success probability is 0.5.
Additional outcomes will be summarized numerically using descriptive statistics
(appropriate point and interval estimates) and graphically (histograms, box-plots, stem
and leaf plots as required).
10. Toxicity grading:
All adverse events will be recorded and reported in accordance to The National Cancer
Institute's published Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
11. Data Storage All study data will be stored within a password secured electronic dataset.
Study data will be accessed only by IRB approved study staff.
12. Timeline:
The estimated period for the feasibility pilot study (n=15) is 6 months starting from signing
the contract. Once IRB approval is attained for the pilot study, patient enrollment will
begin. Patients data and study outcomes will be collected on rolling basis in parallel with
patient enrollment and study execution. Once all data are gathered, data reporting will be
done.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |